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Background: Transarterial chemotherapy infusion (TAI) with lipiodol is a palliative treatment for hepa-
tocellular carcinoma. The aim of this study was to describe the outcomes of TAI from a single scandi-
navian centre between 1995 to 2008.
Methods: The study is a retrospective analyse of prospectively collected data. TAI (doxorubicin, 50 mg
with lipiodol) was administrated every 6 weeks. After 5 treatments, a CT scan was performed, and if the
disease was stable, (RECIST score) treatment was continued.
Results: 57 patients with HCC were treated with TAI. Median age; 72 years (52–84), 41 (71%) men. 52
(91%) had Child-Pugh score A, and 5 (9%) had Child-Pugh B. Nine (16%) patients had a BCLC score A,
19 (33%) B, 29 (51%) C, while none was classified as BCLC D. Twenty nine (51%) patients had a tumour
size  10 cm. In total 254 treatments were performed, a median of 4 (1–20) per patient. Treatment
mortality was 0%. In 30 (53%) patients the treatment strategy was not completed due to deteriorating
clinical conditions. Median survival was 17 months (2–108), 2, 3, and 5-years survival was 34%, 22%, and
13%, respectively. Patients that responded to treatment (n = 23) had a median survival of 26 (13–108)
months compared to 8 (2–48) months for those not fulfilling the treatment plan, p < 0.05. Tumour size 
10 cm, AFP  400 mg/l, and Child-Pugh class B or C were negative prognostic factors for survival,
p < 0.05.
Conclusions: The 5 year survival was 13%, and median survival 17 months. Treatment mortality was
0%. Patients that responded to treatment (40%) had a median survival of 26 months. TAI provides good
palliation but selection of patients is crucial.
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Introduction
Primary hepatocellular carcinoma (HCC) is a common cancer
worldwide and there are indications that its incidence is rising in
the industrialized world.1The diagnosis of HCC is often difficult
to establish early because patients are often asymptomatic.
Patients with clinical symptoms usually present an intermediate
or rather advanced stage at the time of diagnosis and are usually
not suitable for curative treatment with liver resection, liver trans-
plantation or radiofrequency. Only 40% of patients are suitable
for such treatments2 as a result of extensive tumour growth at
diagnosis.
Transarterial chemoembolization (TACE) is the recommended
method for palliative treatment of HCC in patients with medium
to large tumours without extrahepatic spread and sometimes in
multifocal disease.3 Several randomized controlled trials (RCTs)
have been performed to assess the efficacy of symptomatic therapy
vs. that of TACE, without demonstrating a significant difference.
Two RCTs, however, found a modest survival advantage with
TACE.4,5 Several studies with TACE have shown 5-year survival
rates of 20–30%, but these have varied widely in their patient
inclusion criteria.6,7 TACE procedures are commonly used in
Asian populations.8 Transarterial infusion chemotherapy/
transarterial lipiodolization (TAI or TACI) describes the same
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procedure without the use of an embolic agent.9 TAI has been
used for recurrent HCC in the remnant lobe after hemi-
hepatectomy.10 The use of embolic material is, however, not
evidence-based and thus no study has indicated that embolization
has an additive anti-tumour effect when combined with chemo-
therapy. Recently, an RCT comparing TACE with TAI found no
positive effect on survival.11 Nevertheless, TACE seems to be the
preferred method.12 A more modern approach concerns the use of
drug-eluting beads (DEB) in TACE; microparticles uploaded with
a chemotherapeutic drug have shown promising results.13,14 By
contrast, some research has reported transarterial embolization
(TAE) only to be as effective as TACE.15 Superabsorbent polymer
microspheres have been developed for use in embolization, which
is then designated ‘bland embolization’.16 A drawback, at least in
theory, of TAE is that hypoxia has been shown to stimulate vas-
cular endothelial growth factor (VEGF) in animal studies.17 VEGF
is a promoter of tumour growth. Elevated levels have been shown
after TACE procedures in clinical practice.18,19
Transarterial radioembolization (TARE) is also used for unre-
sectable HCC, but so far no survival benefit has been proven.
However, some authors propose that TACE and TARE provide
similar results.20,21 No studies have been performed to compare
these palliative treatments in HCC.
We previously reported our initial results for such methods
based on patients treated between 1988 and 1994.22 Our report
described a poor median survival of only 6 months and a high
number of very early deaths in that earlier series. As a result of
these data, we changed our inclusion and exclusion criteria for this
treatment. The aim of this study was to investigate the effects of
this change by describing outcomes in patients undergoing TAI at
one institution between 1995 and 2008.
Materials and methods
This study is based on 57 consecutive patients with HCC treated
with TAI at the Department of Surgery, University Hospital,
Uppsala, Sweden, from January 1995 to end of December 2008.
The data on these patients were prospectively accumulated using
a computerized patient data register and were analysed retrospec-
tively. The patient data register is legally part of the hospital
patient health record system. The analysis is supported by Swedish
health quality assurance law.
Patient work-up included biochemical laboratory tests (i.e.
bilirubin, alkaline phosphates, transaminases, albumin, INR, crea-
tinine, alpha-fetoprotein [AFP], haemoglobin and platelets), and
computerized tomography (CT) or magnetic resonance imaging
(MRI) scans (number and size of tumours, one or both lobes
affected, ascites). Absence of encephalopathy was judged on clini-
cal grounds. Presence of ascites was judged by the results of the
diagnostic CT scans. The absence of ascites in patients on mild
diuretics was considered to indicate no ascites. Barcelona Clinic
liver cancer (BCLC) scores23 were used to classify patients. Patients
with Child–Pugh grade C scores and patients with thrombosis of
the main portal vein or signs of extrahepatic spread were not
offered TAI.
Statistics
Descriptive statistics are expressed as proportions (%) for
categorical variables. Median and range are used for continuous
variables. Survival after TAI was calculated according to the
Kaplan–Meyer test and the log-rank test was used to compare
survival rates. Statistical significance was defined by a P-value
of <0.05.
Transarterial chemotherapy with doxorubicin
and lipiodol
Treatment was performed by an interventional radiologist. Portal
circulation was confirmed using either ultrasound or prolonged
angiographic imaging. Access was gained through the right
common femoral artery. Selective angiography of the superior
mesenteric artery and the coeliac trunk was performed in order to
determine the arterial anatomy and to detect accessory feeders.
The hepatic artery was then catheterized using a 0.035-inch wire
and a 4-French catheter when possible or a 0.014-inch wire and a
3-French catheter when needed. The catheter was advanced into
the arterial branch supplying the tumour.
Fifty milligrams of doxorubicin (Adriamycin®; Pharmacia &
UpJohn, Inc., Kalamazzoo, MI, USA) was dissolved in 0.44 ml
water and 256 ml Urografin® (Bayer Schering Pharma AG, Berlin,
Germany) to achieve the same specific weight as that of lipiodol
before the solution was mixed with 10 ml lipiodol (Lipiodol Ultra
Fluid®; Guerbet Research, Roissy, France). The solution was slowly
infused under fluoroscopy control using the same amount of
doxorubicin (50 mg) for all patients. Infusion was continued until
the total amount was administered or until local circulatory arrest
was achieved.Generally, the total amount (i.e. 50 mg doxorubicin)
could be administered in the first four or five treatments, after
which the blood supply to the tumour was reduced as a result of
arterial changes and the amount that could be administered
decreased accordingly with every subsequent treatment.
In patients treated during 1995–2002, a diagnostic hepatic
angiography was first performed using the same technique, but
infusing only lipiodol. Two weeks after this procedure a CT scan
was performed to verify the accumulation of lipiodol in the
tumour. Then, approximately 1 month after the CT scan, doxoru-
bicin was added to the infusion, which was performed in the
manner described above. This diagnostic procedure was per-
formed in order to exclude patients in whom no lipiodol accumu-
lation was seen in the tumour as they would not benefit from the
subsequent treatment. As lipiodol accumulation was seen in all
patients, the diagnostic procedure was abandoned and since 2003
treatment has been administered in the first session.
The treatment course was intended to include treatment admin-
istered every 6 weeks during the first 6 months. After five treat-
ments, a CT scan was performed to validate the effect on tumour
size.When tumour regressionorunchanged tumour size according
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to RECIST (response evaluation criteria in solid tumours) score
was seen, 24 the treatment continued every 8 weeks until changes in
the hepatic artery, impairment of the general condition of the
patient or clinical or radiological progression of tumour size were
observed.When tumour progression was detected after five treat-
ments, the patient was excluded from further treatment with TAI
and was offered symptomatic treatment only.
Results
Patient characteristics
Median patient age was 72 years (range: 52–84 years) at the time
of first treatment. A total of 41 of the 57 (71%) patients were men.
Liver blood tests prior to treatment verified liver function within
the Child–Pugh grade A range in 52 (91%) patients and within
Child–Pugh grade B range in five (9%) patients (Table 1). The
lower normal limit for albumin is 36 g/l in our laboratory. The
median albumin value was 36.5 g/l (range: 25–46 g/l); 13 (23%)
patients had an albumin level <36 g/l and none had a level <25 g/l.
Cirrhosis was verified by biopsy in 48 (84%) patients. The
aetiology of cirrhosis was hepatitis B (n = 2), hepatitis C (n = 5),
alcoholic liver disease (n = 9), non-alcoholic steatohepatitis/
metabolic syndrome (n = 7), a-1-antitrypsin deficiency (n = 1),
porphyria (n = 2) and unknown (n = 22). No patients were
treated with sorafenib.
Alpha-fetoprotein was obtained in 36 patients. The median
value in these patients was 28.5 mg/l (range: 1–114 800 mg/l); the
upper limit for normality in this laboratory is 15 mg/l. Six of 36
patients had normal AFP levels.
Tumour characteristics
Diagnosis of HCC was confirmed by biopsy in 53 (92%) patients.
Four patients were diagnosed by typical imaging findings on CT
scan or MRI and ultrasound or elevated AFP levels.
The median tumour size was 10 cm (range: 2–20 cm). Overall,
28 (49%) patients had a tumour size of <10 cm and 10 of these
(18% of all patients) had a tumour size of <5 cm; 29 (51%)
patients had a tumour size 10 cm. Staging by BCLC classifica-
tion indicated nine stage A, 19 stage B, 29 stage C and no stage D
tumours. Sixteen patients had bilobar disease and 29 patients had
multifocal tumours.
Treatment
Patients treated with TAI were assessed as not suitable for surgery
as a result of unresectability (i.e. central tumour, bilobar tumour,
small liver remnant [n = 34]) or cirrhotic livers (n = 11). In addi-
tion, nine patients were elderly or had severe co-morbidities that
excluded them from surgery. Three patients were on the waiting
list for liver transplantation and were treated with TAI as a bridge
to transplantation. No patient with persistent ascites, encephal-
opathy or complications caused by portal hypertension was
offered TAI treatment.
A total of 254 TAI treatments were performed in the 57
patients, giving a median of four treatments per patient (range:
1–20). In 30 (53%) patients, the therapy was concluded before five
treatments had been administered. Eleven patients in this group
received only one treatment. The reasons for ending the treatment
included deterioration of the general clinical condition (n = 13),
tumour progression (n = 4), arterial changes preventing further
infusions (n = 3), portal vein thrombosis after the first treatment
(n = 2), liver failure (n = 2), kidney failure (n = 1), diagnosis of
extrahepatic tumour (n = 1) and patient will (n = 1). One patient
died after two treatments. Two patients underwent liver trans-
plantation.
Of the 27 patients who achieved five treatments, follow-up CT
scans showed regression or unchanged tumour size in 23. Based
on intention to treat, 23 (40%) patients consequently showed
stable disease according to RECIST scores. They were offered
further treatments. Two of these patients underwent liver resec-
tion, which was now considered possible as a result of the tumour
regression. The pathology report following these two liver resec-
tions indicated total necrosis of the tumours with no viable
tumour cells.
Complications associated with treatment
Treatment mortality at 30 days was 0%. The overall complication
rate was 2% (in five of 254 treatments). Complications included
septicaemia (n = 1), ulcer (n = 1), angiographic complications
(bleeding from the groin) (n = 2) and cardiac complication
(n = 1). Slight but clinically evident side-effects of the treatment
were frequently presented and included fever (24 patients, 43%),
nausea (12 patients, 21%) and abdominal pain (12 patients, 21%).
Some patients had more than one symptom. Fifteen (27%)
patients were, however, totally asymptomatic after treatment.
Median length of hospital stay, including the treatment day, was 2
days (range: 1–9 days).
Survival
The overall median survival was 17 months (range: 2–108
months). Kaplan–Meier analysis indicates survival probabilities at
2, 3 and 5 years of 34%, 22% and 13%, respectively (Fig. 1). Two
Table 1 Results of liver blood tests performed prior to treatment in all
patients (n = 57)
Median (range)
Bilirubin, mmol/l 14 (6–107)
Albumin, g/l 36.5 (25–46)
Prothrombin (INR) 1.1 (0.9–1.8)
Alpha-fetoprotein, mg/l 28.5 (1–114 800)
Alkaline phosphatase, mkat/l 4.7 (1.1–69.0)
Aspartataminotranspherase, mkat/l 1.1 (0.1–12.3)
Alaninaminotranspherase, mkat/l 0.7 (0.1–10.1)
Haemoglobin, g/l 128 (75–168)
Platelets, ¥109/l 220 (45–678)
HPB 639
HPB 2010, 12, 637–643 © 2010 International Hepato-Pancreato-Biliary Association
patients were excluded from the survival analyses because they
underwent liver transplantation after the TAI treatment had
begun. However, the two patients who underwent liver resection
after TAI are included in the survival analyses.
Survival correlated to tumour size is illustrated in Fig. 2.
Patients with a tumour size of <10 cm (median: 5.5 cm) (n = 26)
had a median survival of 23 months (range: 3–108 months),
whereas those with a tumour size of 10 cm (median: 11 cm)
(n = 29) had a median survival of 13 months (range: 2–71
months) (P < 0.05). Patients who responded to treatment (i.e.
demonstrated tumour regression or stable disease on the CT scan
following five treatments) had a median survival of 26 months
(range: 13–108 months) (P < 0.05) (Fig. 3). Survival rates at 2, 3
and 5 years in this group of patients were 53%, 37% and 17%,
respectively. The median tumour size was 8.5 cm (range:
2–15 cm) in this subgroup. Patients with bilobar disease (n = 16)
had a median survival of 10 months (range: 4–24 months) com-
pared with 18 months (range: 1.8–108 months) (P < 0.05) in
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Figure 1 Overall survival according to Kaplan-Meier
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Figure 2 Survival in patients with tumour diameter on CT scan  10 cm (n = 29; dashed line) vs <10 cm (n = 26; solid line) calculated
according to Kaplan-Meier, p < 0.05
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patients with unilobar disease (n = 39).Median survival according
to BCLC score was 33, 23 and 12 months for stages A, B and C,
respectively (P < 0.05) (Fig. 4).
Median survival in patients with AFP levels >400 mg/l was 8
months (range: 1.8–19 months), whereas that in patients with
AFP < 400 mg/l was 24 months (range: 2.7–108 months)
(P < 0.05). Survival analysis shows that every point over 5 in the
Child–Pugh score is a negative prognostic factor (Table 2).
Patients with Child–Pugh stage A scores had a median survival of
17 months (range: 3–108 months) compared with 4 months
(range: 2–5 months) in patients with Child–Pugh B scores
(P < 0.05).
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Figure 3 Survival in patients responding to treatment with stationary disease at CT scan control after 5 treatments (n = 23; solid line) vs
patients not responding to or not fulfilling treatment (n = 32; dashed line) according to Kaplan-Meier, p < 0.05
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Figure 4 Survival according to BCLC classification, A (n = 7; solid line), B (n = 19; dashed line), C (n = 29; dotted line), Kaplan-Meier, p < 0.05
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Discussion
Patients with HCC can be offered TACE or TAI as a palliative
treatment, especially for multifocal tumours exceeding 4–5 cm. A
meta-analysis by Llovet et al.25 showed a survival benefit in well-
selected patients. These selection criteria indicate that the grade of
liver function deterioration caused by liver cirrhosis should not
exceed Child–Pugh grade A. Furthermore, thrombosis in the main
portal vein must be excluded.2 In the present study, advanced
tumour size was not an exclusion criterion: 51% of our patients
had a tumour size >10 cm. A few patients with Child–Pugh grade
B scores (n = 5) were included and all of them had very short
survival (median: 4 months; range: 2–15 months).
Similar results were found in an RCT comparing TAI and
TACE.11 The development of DEB-TACE allows for the slow
release of chemotherapy to the tumour, which results in a greater
drug concentration in the tumour and reduces the systemic
effects.13,14 In the present study, only TAI was used in all treat-
ments. Our reason for not using embolic material after chemo-
therapy infusion in this study referred to the theoretical possibility
that the artery would not remain open to allow repeat treatments
every 6 weeks. Although we did not use embolization material,
arterial occlusion was identified in 10 patients following treat-
ment. These 10 patients received a median of six (range: 3–16)
treatments. The fact that TAE in animal studies and TACE in
clinical studies have shown elevated VEGF levels stimulating
tumour growth after treatment may indicate an advantage for the
TAI procedure.17 VEGF levels after TAI should also be studied.
Most patients with HCC are diagnosed at advanced stages
when palliative treatment is the only option. In our previous
series of patients treated with TAI for HCC during 1988–1994,
patients with portal vein thrombosis were included, as were
patients with Child–Pugh grades B and C disease.22 In that
series, 30 of 58 (52%) patients had portal thrombosis at the time
of treatment. In the previous study, treatment-associated mor-
tality was 9% and median survival was only 6 months. Indepen-
dent negative prognostic factors for survival are presence of
portal vein thrombosis and Child–Pugh grade B and C scores, as
also indicated by Greten et al.26 In fact, in this study, every point
above 5 in the Child–Pugh score was associated with decreased
survival (Table 2). Other negative prognostic factors include
bilobar disease, AFP levels >400 mg/l, tumour invasion of the
portal branches, tumour size 10 cm, and low albumin levels.27
In the current study, we verified that bilobar disease,
AFP > 400 mg/l, low albumin levels and tumour size were nega-
tive prognostic factors. However, we cannot indicate whether or
not tumour invasion of the portal branches represents such a
factor as we did not study this issue.
In the current study the median overall survival was 17 months
and treatment mortality was 0%. Actuarial survival rates at 1, 2, 3
and 5 years were 62%, 34%, 22% and 13%, respectively. Another
study with selected patients undergoing TACE reported 1-year
survival of 82% and 2-year survival of 63%.4 Bruix et al.28 reported
a treatment mortality of <4% and Takayasu et al.8 reported TACE-
related mortality of 0.5%. It is perhaps not surprising that the
subgroup of patients who responded to treatment had better sur-
vival. Survival rates at 2, 3 and 5 years were 53%, 37% and 17%,
respectively, among such patients. Response to treatment was also
identified as an independent predictor for survival by Llovet et al.4
The current study has some limitations. Firstly, it is a retrospec-
tive analysis of a prospectively accumulated patient data material
based on a fairly small sample size collected over several years.
Secondly, this study was uncontrolled. Thirdly, the published
results with which the findings of the current study are compared
are mostly based on TACE treatment procedures. In our experi-
ence, the lack of other palliative treatment modalities for
advanced tumour stages in patients with a good general clinical
condition, well-preserved liver function and no other factors for
exclusion oftenmakes TAI treatment the obvious choice.A total of
51% of patients in this study had an advanced tumour size
(10 cm). Systemic therapy with sorafenib was introduced
during the last years of our study period. Sorafenib treatment
offers a survival benefit of 2–3 months compared with best pal-
liation29 and thus would not appear to be an obviously attractive
alternative to patients suitable for TAI. However, an RCT compar-
ing outcomes in TAI and sorafenib would be of great interest.
In the current study, 30 patients were unable to fulfil the
planned course of five treatments because of deterioration in their
general clinical condition, tumour progression or for similar
reasons, and 11 of these patients received only one treatment. This
demonstrates that the selection of patients suitable for TACE/TAI
is crucial and, in all likelihood, could be further improved. A
European RCT showed that only 12% of the whole HCC popula-
tion was suitable for TACE.4
In summary, TAI was demonstrated to provide good longterm
effects including a 5-year survival of 13% in this group of HCC
patients. However, several patients were unable to fulfil the
planned treatments. Those patients who responded objectively
to treatment achieved the best effect. Patients with unilobar
tumours or tumour size <10 cm achieved greater benefit than
those with bilobar disease or tumours >10 cm in size. Any devia-
tion from absolutely normal liver function was associated with
poorer effect.
Conflicts of interest
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Table 2 Median survival according to Child–Pugh score
Child–Pugh score 5 (n = 40) 6 (n = 10) 7 (n = 2) 8 (n = 2) 9 (n = 1)
Median survival, months 19.0 15.3 4.5 5.2 3.5
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